Compare UNTY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | ADCT |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.6M | 439.8M |
| IPO Year | 1997 | 2020 |
| Metric | UNTY | ADCT |
|---|---|---|
| Price | $53.96 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $65.00 | $7.60 |
| AVG Volume (30 Days) | 46.8K | ★ 635.1K |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ 39.66 | N/A |
| EPS | ★ 5.67 | N/A |
| Revenue | ★ $127,871,000.00 | $75,209,000.00 |
| Revenue This Year | $11.57 | $12.48 |
| Revenue Next Year | $8.52 | $5.12 |
| P/E Ratio | $9.52 | ★ N/A |
| Revenue Growth | ★ 23.99 | 6.35 |
| 52 Week Low | $36.65 | $1.05 |
| 52 Week High | $57.24 | $4.80 |
| Indicator | UNTY | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 49.60 |
| Support Level | $51.31 | $3.25 |
| Resistance Level | $53.11 | $3.81 |
| Average True Range (ATR) | 1.71 | 0.22 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 53.05 | 63.28 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).